Cinfa Ambroxol Cinfa 6 Mg/Ml Syrup 200 Ml
Cinfa Ambroxol Cinfa 6 Mg/Ml Syrup 200 Ml
Cinfa Ambroxol Cinfa 6 Mg/Ml Syrup 200 Ml
Ambroxol Cinfa 6 Mg/Ml Syrup 200 Ml
ACTION AND MECHANISM
- Mucolytic, expectorant. Ambroxol is the N-desmethyl-bromhexine, the active metabolite of bromhexine. Its administration leads to a decrease in the viscosity of bronchial secretions and an increase in their volume, while favoring their expulsion.
Its mechanism of action is unknown, but it could be related to the increase in the synthesis of sialomucins due to activation of sialyl-transferase, which would restore the normal glycoprotein composition of bronchial mucosa secretion, and would normalize the viscoelasticity of bronchial mucus.
It could also stimulate the mucous glands of the bronchial epithelium, increase lysozyme levels, which would cause the breakdown of mucopolysaccharides, and stimulate mucociliary activity.
PHARMACOKINETICS
- Absorption: it is rapidly and completely absorbed after oral administration, reaching a cmax of 88.8 ng/ml after 1-2.5 h (30 mg po, immediate release) or 6.5 h (prolonged release forms). After oral administration, it undergoes a first-pass effect, eliminating 30% of the dose. Its bioavailability is 79%.
Effect of food : they have no clinically significant effect on the pharmacokinetics of ambroxol.
- Distribution: rapid distribution in the body, with a t1/2 distribution of 1.3 h. It tends to accumulate especially in the lungs, reaching tissue concentrations up to 17 times the cp. Plasma protein binding is 90% and Vd 552 l. Ambroxol crosses the placenta and is excreted in milk.
- Metabolism: it is metabolized in the liver by hydrolysis and glucuronoconjugation through CYP3A4, giving rise to dibromoanthranilic acid (10%) and other metabolites in small amounts.
- Elimination: it is eliminated in urine (83%), recovering 26% as conjugates and 6% unchanged. The t1/2 is 10 h and the CLt is 660 ml/min.
Pharmacokinetics in special situations :
- Renal impairment: pharmacokinetic data are not available.
- Hepatic failure: cp increases 1.3-2 times.
No significant pharmacokinetic differences due to age or sex have been found.
INDICATIONS
- Reduction of [BRONCHIAL HYPERVISCOSITY] in [COMMON COLD] and [FLU].
POSOLOGY
"AMBROXOL 6 mg/ml SYRUP":
- Adults and adolescents over 12 years: 5 ml, 3 times a day for 2-3 days. Subsequently, 5 ml 2 times a day.
- Children from 6 to 12 years: 2.5 ml, 2-3 times a day.
- Children from 2 to 5 years: 1.25 ml, 3 times a day.
- Children < 2 years: not recommended.
- Elderly: no specific dosage recommendations have been made.
Duration of treatment : should not exceed 4-5 days without consulting a doctor.
DOSAGE IN RENAL FAILURE
It may be necessary to reduce the dose or increase the interval between dosing.
DOSAGE IN LIVER FAILURE
It may be necessary to reduce the dose or increase the interval between dosing.
CONTRAINDICATIONS
- Hypersensitivity to ambroxol, bromhexine or any other component of the medication.
- Children < 2 years. Risk of bronchial obstruction.
PRECAUTIONS
- Patients with severe [KIDNEY INSUFFICIENCY] (CLcr < 30 ml/min) or severe [LIVER INSUFFICIENCY] (Child-Pugh class C), due to the risk of accumulation.
- Gastric damage. The administration of mucolytics has been related to disruption of the gastric protective barrier and gastric damage. Evaluate its use in patients with a history of [GASTRITIS] or [PEPTICA ULCERA].
- Skin reactions. The administration of ambroxol has been related to the appearance of serious and life-threatening skin adverse reactions, such as [TOXIC EPIDERMAL NECROLYSIS] or [STEVENS-JOHNSON SYNDROME]. In the event of appearance or worsening of skin or mucous membrane lesions, ambroxol will be discontinued and a diagnosis of the patient will be made.
PRECAUTIONS RELATED TO EXCIPIENTS
- Because it contains benzoic acid as an excipient, it may increase the risk of [JAUNDICE] in newborns (up to 4 weeks of age).
- This medicine contains sorbitol. Patients with hereditary [FRUCTOSE INTOLERANCE] should not take this medication.
ADVICE TO THE PATIENT
- Drink plenty of water during treatment.
- Do not use antitussives while using ambroxol.
- Consult with the doctor and/or pharmacist if the symptoms worsen or do not improve in 5 days, or if fever, headache or sore throat appears.
- Inform your doctor and/or pharmacist if skin rashes appear during treatment, sometimes associated with the appearance of blisters or lesions on the mucous membranes.
SPECIAL WARNINGS
- The use of mucolytics and expectorants in children under 2 years of age is contraindicated due to the risk of bronchial obstruction.
- In case of appearance of cutaneous eruptions on the skin or mucous membranes, ambroxol will be discontinued and the possibility of conditions such as toxic epidermal necrolysis or Stevens-Johnson syndrome will be evaluated.
PREGNANCY
Animal safety : Ambroxol did not cause teratogenic or embryotoxic effects at doses of 3,000 mg/kg/24 h (rat) or 200 mg/kg/24 h (rabbit). Cases of decreased fetal body weight and the number of live pups were reported at maternotoxic doses.
Safety in humans : Clinical use has not revealed any adverse effects on pregnancy or postnatal development when administered from the 28th week of gestation. There are no adequate and well-controlled studies in humans. Its administration is only accepted if there are no safer therapeutic alternatives, and the benefits outweigh the possible risks.
Effects on fertility : Ambroxol did not give rise to secondary effects on fertility in male or female animals at doses of 500 mg/kg/24 h. No specific studies have been conducted in humans.
LACTATION
Safety in animals: no data available.
Safety in humans: Ambroxol is excreted in milk. The consequences that it could have for the infant are unknown. Its administration during lactation is not recommended.
CHILDREN
The use of mucolytics in children under 2 years of age has been associated with the appearance of bronchial obstruction, as a consequence of increased production and fluidization of bronchial secretion and insufficient bronchial drainage. Therefore, the use of mucolytics in these children is contraindicated.
In older children, the pharmaceutical form and dose should be adapted to the age of the child ( see Dosage ).
ADVANCED AGE
No specific problems have been described in the elderly that require a dose readjustment.
EFFECTS ON DRIVING
It does not seem likely that ambroxol could adversely affect the ability to drive.
ADVERSE REACTIONS
Adverse reactions are described according to each frequency interval, being considered very common (>10%), common (1-10%), uncommon (0.1-1%), rare (0.01-0.1%), very rare (<0.01%) or unknown frequency (cannot be estimated from the available data).
- Digestive: frequent [NAUSEA], [DYSGEUSIA], [HYPOESTHESIS] oral; uncommon [VOMITING], [DIARRHEA], [DYSPEPSIA], [ABDOMINAL PAIN], [DRY MOUTH]; rare dry throat.
- Dermatological: rare [EXANTEMATIC ERUPTIONS], [URTICARIA]; unknown frequency [ERYTHEMA MULTIFORME], [STEVENS-JOHNSON SYNDROME], [TOXIC EPIDERMAL NECROLYSIS], acute generalized exanthematous pustulosis.
- Allergic: rare [HYPERSENSITIVITY REACTIONS]; unknown frequency [ANAPHYLAXIA], [ANGIOEDEMA], [PRURITUS].
OVERDOSE
Symptoms : Serious reactions due to ambroxol poisoning have not been reported. As a general rule, the administration of doses of 15 mg/kg/24 h (iv) or 25 mg/kg/24 h (po) was well tolerated. Overdose symptoms included nervousness and diarrhea. In case of significant overdose, drooling, nausea and vomiting and hypotension have been reported.
Measures to take :
- Antidote: there is no specific antidote.
- General elimination measures: the establishment of measures such as induced emesis or gastric lavage is not indicated, except in the case of very serious poisoning. Forced diuresis or dialysis do not appear to be effective measures for the treatment of overdose due to their high plasma protein binding.
- Patient care: keep the respiratory tract free of secretions, lying the patient down and performing a bronchial aspiration.
- Treatment: symptomatic treatment.
| Brand: | Cinfa |
| Isin: | IN07UJWYQI1R |
This product is not available in the selected country
In Stock
Backordered
Out of Stock
IBspot Buyer Protection
Shop confidently on IBspot, receive your item as described or your money back for eligible orders. Learn Program Terms
GUARANTEED SAFE CHECKOUT
-
FREE Shipping
We offer FREE SHIPPING to all domestic orders.
-
EXCELLENT SUPPORT
We provide 24/7 online customer support via email.
-
MONEY BACK GUARANTEE
30 days money back guarantee, no additional fee charged.
Ambroxol Cinfa 6 Mg/Ml Syrup 200 Ml
ACTION AND MECHANISM
- Mucolytic, expectorant. Ambroxol is the N-desmethyl-bromhexine, the active metabolite of bromhexine. Its administration leads to a decrease in the viscosity of bronchial secretions and an increase in their volume, while favoring their expulsion.
Its mechanism of action is unknown, but it could be related to the increase in the synthesis of sialomucins due to activation of sialyl-transferase, which would restore the normal glycoprotein composition of bronchial mucosa secretion, and would normalize the viscoelasticity of bronchial mucus.
It could also stimulate the mucous glands of the bronchial epithelium, increase lysozyme levels, which would cause the breakdown of mucopolysaccharides, and stimulate mucociliary activity.
PHARMACOKINETICS
- Absorption: it is rapidly and completely absorbed after oral administration, reaching a cmax of 88.8 ng/ml after 1-2.5 h (30 mg po, immediate release) or 6.5 h (prolonged release forms). After oral administration, it undergoes a first-pass effect, eliminating 30% of the dose. Its bioavailability is 79%.
Effect of food : they have no clinically significant effect on the pharmacokinetics of ambroxol.
- Distribution: rapid distribution in the body, with a t1/2 distribution of 1.3 h. It tends to accumulate especially in the lungs, reaching tissue concentrations up to 17 times the cp. Plasma protein binding is 90% and Vd 552 l. Ambroxol crosses the placenta and is excreted in milk.
- Metabolism: it is metabolized in the liver by hydrolysis and glucuronoconjugation through CYP3A4, giving rise to dibromoanthranilic acid (10%) and other metabolites in small amounts.
- Elimination: it is eliminated in urine (83%), recovering 26% as conjugates and 6% unchanged. The t1/2 is 10 h and the CLt is 660 ml/min.
Pharmacokinetics in special situations :
- Renal impairment: pharmacokinetic data are not available.
- Hepatic failure: cp increases 1.3-2 times.
No significant pharmacokinetic differences due to age or sex have been found.
INDICATIONS
- Reduction of [BRONCHIAL HYPERVISCOSITY] in [COMMON COLD] and [FLU].
POSOLOGY
"AMBROXOL 6 mg/ml SYRUP":
- Adults and adolescents over 12 years: 5 ml, 3 times a day for 2-3 days. Subsequently, 5 ml 2 times a day.
- Children from 6 to 12 years: 2.5 ml, 2-3 times a day.
- Children from 2 to 5 years: 1.25 ml, 3 times a day.
- Children < 2 years: not recommended.
- Elderly: no specific dosage recommendations have been made.
Duration of treatment : should not exceed 4-5 days without consulting a doctor.
DOSAGE IN RENAL FAILURE
It may be necessary to reduce the dose or increase the interval between dosing.
DOSAGE IN LIVER FAILURE
It may be necessary to reduce the dose or increase the interval between dosing.
CONTRAINDICATIONS
- Hypersensitivity to ambroxol, bromhexine or any other component of the medication.
- Children < 2 years. Risk of bronchial obstruction.
PRECAUTIONS
- Patients with severe [KIDNEY INSUFFICIENCY] (CLcr < 30 ml/min) or severe [LIVER INSUFFICIENCY] (Child-Pugh class C), due to the risk of accumulation.
- Gastric damage. The administration of mucolytics has been related to disruption of the gastric protective barrier and gastric damage. Evaluate its use in patients with a history of [GASTRITIS] or [PEPTICA ULCERA].
- Skin reactions. The administration of ambroxol has been related to the appearance of serious and life-threatening skin adverse reactions, such as [TOXIC EPIDERMAL NECROLYSIS] or [STEVENS-JOHNSON SYNDROME]. In the event of appearance or worsening of skin or mucous membrane lesions, ambroxol will be discontinued and a diagnosis of the patient will be made.
PRECAUTIONS RELATED TO EXCIPIENTS
- Because it contains benzoic acid as an excipient, it may increase the risk of [JAUNDICE] in newborns (up to 4 weeks of age).
- This medicine contains sorbitol. Patients with hereditary [FRUCTOSE INTOLERANCE] should not take this medication.
ADVICE TO THE PATIENT
- Drink plenty of water during treatment.
- Do not use antitussives while using ambroxol.
- Consult with the doctor and/or pharmacist if the symptoms worsen or do not improve in 5 days, or if fever, headache or sore throat appears.
- Inform your doctor and/or pharmacist if skin rashes appear during treatment, sometimes associated with the appearance of blisters or lesions on the mucous membranes.
SPECIAL WARNINGS
- The use of mucolytics and expectorants in children under 2 years of age is contraindicated due to the risk of bronchial obstruction.
- In case of appearance of cutaneous eruptions on the skin or mucous membranes, ambroxol will be discontinued and the possibility of conditions such as toxic epidermal necrolysis or Stevens-Johnson syndrome will be evaluated.
PREGNANCY
Animal safety : Ambroxol did not cause teratogenic or embryotoxic effects at doses of 3,000 mg/kg/24 h (rat) or 200 mg/kg/24 h (rabbit). Cases of decreased fetal body weight and the number of live pups were reported at maternotoxic doses.
Safety in humans : Clinical use has not revealed any adverse effects on pregnancy or postnatal development when administered from the 28th week of gestation. There are no adequate and well-controlled studies in humans. Its administration is only accepted if there are no safer therapeutic alternatives, and the benefits outweigh the possible risks.
Effects on fertility : Ambroxol did not give rise to secondary effects on fertility in male or female animals at doses of 500 mg/kg/24 h. No specific studies have been conducted in humans.
LACTATION
Safety in animals: no data available.
Safety in humans: Ambroxol is excreted in milk. The consequences that it could have for the infant are unknown. Its administration during lactation is not recommended.
CHILDREN
The use of mucolytics in children under 2 years of age has been associated with the appearance of bronchial obstruction, as a consequence of increased production and fluidization of bronchial secretion and insufficient bronchial drainage. Therefore, the use of mucolytics in these children is contraindicated.
In older children, the pharmaceutical form and dose should be adapted to the age of the child ( see Dosage ).
ADVANCED AGE
No specific problems have been described in the elderly that require a dose readjustment.
EFFECTS ON DRIVING
It does not seem likely that ambroxol could adversely affect the ability to drive.
ADVERSE REACTIONS
Adverse reactions are described according to each frequency interval, being considered very common (>10%), common (1-10%), uncommon (0.1-1%), rare (0.01-0.1%), very rare (<0.01%) or unknown frequency (cannot be estimated from the available data).
- Digestive: frequent [NAUSEA], [DYSGEUSIA], [HYPOESTHESIS] oral; uncommon [VOMITING], [DIARRHEA], [DYSPEPSIA], [ABDOMINAL PAIN], [DRY MOUTH]; rare dry throat.
- Dermatological: rare [EXANTEMATIC ERUPTIONS], [URTICARIA]; unknown frequency [ERYTHEMA MULTIFORME], [STEVENS-JOHNSON SYNDROME], [TOXIC EPIDERMAL NECROLYSIS], acute generalized exanthematous pustulosis.
- Allergic: rare [HYPERSENSITIVITY REACTIONS]; unknown frequency [ANAPHYLAXIA], [ANGIOEDEMA], [PRURITUS].
OVERDOSE
Symptoms : Serious reactions due to ambroxol poisoning have not been reported. As a general rule, the administration of doses of 15 mg/kg/24 h (iv) or 25 mg/kg/24 h (po) was well tolerated. Overdose symptoms included nervousness and diarrhea. In case of significant overdose, drooling, nausea and vomiting and hypotension have been reported.
Measures to take :
- Antidote: there is no specific antidote.
- General elimination measures: the establishment of measures such as induced emesis or gastric lavage is not indicated, except in the case of very serious poisoning. Forced diuresis or dialysis do not appear to be effective measures for the treatment of overdose due to their high plasma protein binding.
- Patient care: keep the respiratory tract free of secretions, lying the patient down and performing a bronchial aspiration.
- Treatment: symptomatic treatment.
Shipping Summary:
- Packages are shipped from Monday to Friday.
- The usual time for processing an order is 1 to 3 business days, but may vary depending on the availability of products ordered. This period excludes delivery times, which depend on your geographic location.
- We provide tracking for every order. Tracking will be available once your product is shipped. Each individual product may be shipped from different fulfillment centers across the globe as our product research team spends the time to source quality yet affordable products.
Estimated delivery times:
- Standard Shipping: 3-7 business days
- Expedited Shipping: 2-5 business days
- International Shipping: 10 - 15 business days
Please note that these are estimates, not guarantees. Delivery time depends on a number of variables, and there may be delays such as bad weather affecting air transport, or a package being held for inspection by Customs. ibspot is not liable for any delays in international transportation or customs clearance.
Shipments can be delivered directly to most addresses, except post office boxes. However, in certain remote areas, there may be an additional delivery charge or you may need to pick up your package from the closest service location of ibspot's shipping partner.
Shipping Status:
As soon as your order ships, you'll receive a shipping confirmation email that includes your tracking number.
If you don't receive a shipping confirmation email right away, don't worry! We know the delivery date or date range provided at checkout and we'll be sure to deliver the items within that timeframe.
Order changes:
Please contact our customer support if the order needs to be canceled or modified.
Item not received:
If you've successfully placed an order and haven't received it yet while the tracking status shows it's delivered. you'd wish to contact the carrier to hunt out your Cover as once the item is Covered we have control over it (once it’s by the carrier), but if still persists kindly email us
Damaged Parcel
If your package has been delivered in a PO Box, please note that we are not responsible for any damage that may result (consequences of extreme temperatures, theft, etc.).
If you have any questions regarding shipping or want to know about the status of an order, please contact us or email to support@ibspot.com.
Please Read Our Return & Refund Policy Carefully:
Return:
You may return most items within 30 days of delivery for a full refund.
To be eligible for a return, your item must be unused and in the same condition that you received it. It must also be in the original packaging.
Several types of goods are exempt from being returned. Perishable goods such as food, flowers, newspapers or magazines cannot be returned. We also do not accept products that are intimate or sanitary goods, hazardous materials, or flammable liquids or gases.
Additional non-returnable items:
- Gift cards
- Downloadable software products
- Some health and personal care items
To complete your return, we require a tracking number, which shows the items which you already returned to us.
There are certain situations where only partial refunds are granted (if applicable)
- Book with obvious signs of use
- CD, DVD, VHS tape, software, video game, cassette tape, or vinyl record that has been opened
- Any item not in its original condition, is damaged or missing parts for reasons not due to our error
- Any item that is returned more than 30 days after delivery
Items returned to us as a result of our error will receive a full refund,some returns may be subject to a restocking fee of 7% of the total item price, please contact a customer care team member to see if your return is subject. Returns that arrived on time and were as described are subject to a restocking fee.
Items returned to us that were not the result of our error, including items returned to us due to an invalid or incomplete address, will be refunded the original item price less our standard restocking fees.
You should expect to receive your refund within four weeks of giving your package to the return shipper, however, in many cases you will receive a refund more quickly. This time period includes the transit time for us to receive your return from the shipper (5 to 10 business days), the time it takes us to process your return once we receive it (3 to 5 business days), and the time it takes your bank to process our refund request (5 to 10 business days).
If you need to return an item, please Contact Us with your order number and details about the product you would like to return. We will respond quickly with instructions for how to return items from your order.
Shipping Cost
We'll pay the return shipping costs if the return is a result of our error (you received an incorrect or defective item, etc.). In other cases, you will be responsible for paying for your own shipping costs for returning your item. Shipping costs are non-refundable. If you receive a refund, the cost of return shipping will be deducted from your refund.
Depending on where you live, the time it may take for your exchanged product to reach you, may vary.
If you are shipping an item over $75, you should consider using a trackable shipping service or purchasing shipping insurance. We don’t guarantee that we will receive your returned item.
Refund:
- Purchases may be returned within 30 days of the shipping date for a refund.
- Refund will be issued to your original form of payment.
- Refunds for orders purchased with IBSPOT Gift Cards and/or IBSPOT Notes will be issued as a IBSPOT Gift Card and mailed to the original billing address. Gift cards cannot be redeemed for cash unless required by law.
Refund Processing
• Returns to a IBSPOT store will be refunded to the original form of payment or gift card. • Mail-in returns with our prepaid return label will be refunded back to the original form of payment within 3-5 business days after we receive your return. Please allow 5-7 business days for your return to arrive at our Returns Center.
• Note: It may take a few days until your bank posts the refund to your account.
Claims:
Claims related to the product. Be sure to check the details of your purchase carefully before you make the payment, and check the contents of the package(s) promptly upon receipt. If you have a problem with the product, visit our Support Center to find out about return shipping arrangements.
WHICH CIRCUMSTANCES WE OFFER RETURND & REFUND:
WRONG PRODUCT:
If you discover your order is flawed please contact us Mail: support@ibspot.com. With photos of the wrong product we will providing a return shipping label. Once it is tracking we will ship a replacement a product immediately.
Damages and issues
Please inspect your order upon reception and contact us immediately if the item is defective, damaged or if you receive the wrong item, so that we can evaluate the issue and make it right.
Exceptions / non-returnable items
Certain types of items cannot be returned, like perishable goods (such as food, flowers, or plants), custom products (such as special orders or personalized items), and personal care goods (such as beauty products). We also do not accept returns for hazardous materials, flammable liquids, or gases. Please get in touch if you have questions or concerns about your specific item. Unfortunately, we cannot accept returns on sale items or gift cards.
Exchanges
The fastest way to ensure you get what you want is to return the item you have, and once the return is accepted, make a separate purchase for the new item.
Oops!
Sorry, it looks like some products are not available in selected quantity.
